Scott Kopetz
Scott Kopetz
University of Texas MD Anderson Cancer Center
Dirección de correo verificada de - Página principal
Citado por
Citado por
The consensus molecular subtypes of colorectal cancer
J Guinney, R Dienstmann, X Wang, A De Reynies, A Schlicker, ...
Nature medicine 21 (11), 1350-1356, 2015
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
MJ Overman, R McDermott, JL Leach, S Lonardi, HJ Lenz, MA Morse, ...
The lancet oncology 18 (9), 1182-1191, 2017
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer
MJ Overman, S Lonardi, KYM Wong, HJ Lenz, F Gelsomino, M Aglietta, ...
Journal of clinical oncology 36 (8), 773-779, 2018
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy
S Kopetz, GJ Chang, MJ Overman, C Eng, DJ Sargent, DW Larson, ...
Journal of clinical oncology 27 (22), 3677, 2009
Towards the introduction of the ‘Immunoscore’in the classification of malignant tumours
J Galon, B Mlecnik, G Bindea, HK Angell, A Berger, C Lagorce, A Lugli, ...
The Journal of pathology 232 (2), 199-209, 2014
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ...
New England Journal of Medicine 381 (17), 1632-1643, 2019
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
R Dienstmann, L Vermeulen, J Guinney, S Kopetz, S Tejpar, J Tabernero
Nature reviews cancer 17 (2), 79-92, 2017
Cancer classification using the Immunoscore: a worldwide task force
J Galon, F Pagès, FM Marincola, HK Angell, M Thurin, A Lugli, I Zlobec, ...
Journal of translational medicine 10, 1-10, 2012
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
B Tran, S Kopetz, J Tie, P Gibbs, ZQ Jiang, CH Lieu, A Agarwal, DM Maru, ...
Cancer 117 (20), 4623-4632, 2011
Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer
S Kopetz, J Desai, E Chan, JR Hecht, PJ O'Dwyer, D Maru, V Morris, ...
Journal of clinical oncology 33 (34), 4032, 2015
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases
DG Blazer III, Y Kishi, DM Maru, S Kopetz, YS Chun, MJ Overman, ...
Journal of Clinical Oncology 26 (33), 5344-5351, 2008
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer
H Ling, R Spizzo, Y Atlasi, M Nicoloso, M Shimizu, RS Redis, N Nishida, ...
Genome research 23 (9), 1446-1461, 2013
Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for …
AR Sepulveda, SR Hamilton, CJ Allegra, W Grody, AM Cushman-Vokoun, ...
American journal of clinical pathology 147 (3), 221-260, 2017
Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests
RFA Logan, J Patnick, C Nickerson, L Coleman, MD Rutter, ...
Gut 61 (10), 1439-1446, 2012
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
T Yoshino, D Arnold, H Taniguchi, G Pentheroudakis, K Yamazaki, RH Xu, ...
Annals of Oncology 29 (1), 44-70, 2018
Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases
YS Chun, JN Vauthey, P Boonsirikamchai, DM Maru, S Kopetz, ...
Jama 302 (21), 2338-2344, 2009
Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600–mutant colorectal cancer
RB Corcoran, CE Atreya, GS Falchook, EL Kwak, DP Ryan, JC Bendell, ...
Journal of clinical oncology 33 (34), 4023, 2015
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with …
S Kopetz, PM Hoff, JS Morris, RA Wolff, C Eng, KY Glover, R Adinin, ...
Journal of clinical oncology 28 (3), 453, 2010
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).
S Kopetz, SL McDonough, VK Morris, HJ Lenz, AM Magliocco, CE Atreya, ...
Journal of Clinical Oncology 35 (4_suppl), 520-520, 2017
KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer
W Liao, MJ Overman, AT Boutin, X Shang, DI Zhao, P Dey, J Li, G Wang, ...
Cancer cell 35 (4), 559-572. e7, 2019
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20